Evidence map›Paper›PMID 39670996›Full record

ArticleThe Journal of experimental medicine2025

Mechanosensing regulates pDC activation in the skin through NRF2 activation.

Vidyanath Chaudhary, Bikash Mishra, Marie Dominique Ah Kioon, Yong Du, Lionel B Ivashkiv, Mary K Crow, Franck J Barrat

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. CAR-T cells in systemic sclerosis.Clinical rheumatology · 2026
    Review
  4. Article
  5. PIEZO1 in Immune Cells: From Force to Function.Results and problems in cell differentiation · 2026
    Review
  6. The immunoproteasome regulates ILC2 responses by modulating mitochondrial capacity.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Review
  8. PFKFB2-Driven Glycolysis Promotes Dendritic Cell Maturation and Exacerbates Acute Lung Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vidyanath ChaudharyHSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery , New York, NY, USA.ORCID 0000-0002-6000-7517
Bikash MishraHSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery , New York, NY, USA.ORCID 0000-0002-7351-2096
Marie Dominique Ah KioonHSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery , New York, NY, USA.ORCID 0000-0003-2319-0444
Yong DuHSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery , New York, NY, USA.ORCID 0000-0003-2986-6249
Lionel B IvashkivHSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery , New York, NY, USA.ORCID 0000-0002-9951-0646
Mary K CrowHSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery , New York, NY, USA.ORCID 0000-0002-7881-2020
Franck J BarratHSS Research Institute, Inflammation and Autoimmunity Program, Hospital for Special Surgery , New York, NY, USA.ORCID 0000-0002-0735-0850

Funding

STEROID THERAPY AND CYTOKINES IN RHEUMATIC DISEASESR01AI046712 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 2000 to 2025
$12.5M
Fc Receptors &Cytokine Balance in Rheumatoid ArthritisR01AR050401 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Lionel B Ivashkiv · 2004 to 2026
$7.4M
Role of plasmacytoid dendritic cells in autoimmunityR01AI132447 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI BARRAT, FRANCK · 2018 to 2022
$2.2M
NIAID NIH HHS R01 AI046712NIAID NIH HHS R01 AI132447NIAMS NIH HHS R01 AR050401NIH HHS 1R01AI132447Scleroderma Research Foundation
6 · The paper itself

Abstract

Plasmacytoid DCs (pDCs) infiltrate the skin, chronically produce type I interferon (IFN-I), and promote skin lesions and fibrosis in autoimmune patients. However, what controls their activation in the skin is unknown. Here, we report that increased stiffness inhibits the production of IFN-I by pDCs. Mechanistically, mechanosensing activates stress pathways including NRF2, which induces the pentose phosphate pathway and reduces pyruvate levels, a product necessary for pDC responses. Modulating NRF2 activity in vivo controlled the pDC response, leading to resolution or chronic induction of IFN-I in the skin. In systemic sclerosis (SSc) patients, although NRF2 was induced in skin-infiltrating pDCs, as compared with blood pDCs, the IFN response was maintained. We observed that CXCL4, a profibrotic chemokine elevated in fibrotic skin, was able to overcome stiffness-mediated IFN-I inhibition, allowing chronic IFN-I responses by pDCs in the skin. Hence, these data identify a novel regulatory mechanism exerted by the skin microenvironment and identify points of dysregulation of this mechanism in patients with skin inflammation and fibrosis.

Indexed as

Dendritic CellsInterferon Type INF-E2-Related Factor 2SkinAnimalsFemaleFibrosisHumansMechanotransduction, CellularMiceMice, Inbred C57BLScleroderma, SystemicInterferon Type INFE2L2 protein, humanNF-E2-Related Factor 2

Identifiers

PMID39670996
PMCPMC11639951

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.